# Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Study · id `cardio:ct-nct06122779` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06122779](<https://clinicaltrials.gov/study/NCT06122779>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06122779

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 227 participants.

## Technical summary

Registry record NCT06122779. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-07 (actual); primary completion 2026-12-14 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 227 participants (enrolled count; ClinicalTrials.gov record NCT06122779, source copy `cardio:ctgov-nct06122779-2026-07-30`, retrieved 2026-10-26)
- Started: 2023-11-07 (actual) (ClinicalTrials.gov record NCT06122779, source copy `cardio:ctgov-nct06122779-2026-07-30`, retrieved 2026-10-26)
- Primary completion: 2026-12-14 (anticipated) (ClinicalTrials.gov record NCT06122779, source copy `cardio:ctgov-nct06122779-2026-07-30`, retrieved 2026-10-26)
- Completion: 2026-12-14 (anticipated) (ClinicalTrials.gov record NCT06122779, source copy `cardio:ctgov-nct06122779-2026-07-30`, retrieved 2026-10-26)
- Countries: United States; Argentina; Canada; China; Israel; Italy; Japan; Poland; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT06122779, source copy `cardio:ctgov-nct06122779-2026-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06122779-2026-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
- Acronym: AURORA-HFpEF
- Condition: Heart Failure
- Intervention (Drug): BMS-986435
- Intervention (Other): Placebo
- Lead sponsor: Bristol-Myers Squibb
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

## Provenance

Content hash: 76b7a972121f6df976e66708643f65882a2bec76db1376332bfccbb708b04c73
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
